Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  16 (2024)
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 16 , ISSUE 2 ( March-April, 2024 ) > List of Articles

REVIEW ARTICLE

How to Protect Fertility Potential in Endometriosis

Fahmida Rashid

Keywords : Aromatase inhibitors, Endometriosis, Fertility preservation, GnRH agonist, GnRH antagonist, Modified surgery, Ovarian reserve

Citation Information : Rashid F. How to Protect Fertility Potential in Endometriosis. J South Asian Feder Obs Gynae 2024; 16 (2):134-144.

DOI: 10.5005/jp-journals-10006-2380

License: CC BY-NC 4.0

Published Online: 23-02-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Abstract

Endometriosis is a chronic condition affecting fertile women with many adverse effects. Subfertility is one of the main issues. The ovarian reserve (OR) gradually decreases due to physical and immunological factors associated with endometriosis. Hence, early and prompt treatment of endometriosis and subfertility caused by endometriosis can improve a woman's quality of life. The article aims to shed light on the currently available options for fertility-preserving management of endometriosis. Endometriosis-related subfertility should be managed judiciously and individually according to age, parity, the extent of the disease, and the patient's social aspect. Subfertility management is approached by medical management but sometimes demands a surgical approach. But, surgery is very detrimental to OR. That is why, while managing endometriosis, one should aim to protect fertility potential. To approach fertility protection, suppressive therapy, which halts the disease process and prevents follicular loss due to “OMA,” is an option for adolescents and women who want to postpone pregnancy for a certain period. If one needs surgical intervention for treatment, a modified surgical approach to minimize follicular loss would be preferable to protect the OR. Also, while treating subfertility, the approach should be to reduce the time to live birth to avoid the consequences of the recurrence of the disease. And finally, in adolescent endometriosis and women who need repeated surgery, fertility preservation by tissue freezing might help them for future fertility in the present day.

HTML PDF Share
  1. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril 2012;98(3):511–519. DOI: 10.1016/j.fertnstert.2012.06.029.
  2. Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004;160: 784–796. DOI: 10.1093/aje/kwh275.
  3. Guo SW, Wang Y. Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women. Fertil Steril 2006;86(6):1584–1595. DOI: 10.1016/j.fertnstert.2006.04.040.
  4. Hughesdon PE. The structure of endometrial cysts of the ovary. J Obstet Gynaecol Br Emp 1957;64(4):481–487. DOI: 10.1111/j.1471-0528.1957.tb06276.x.
  5. Brosens IA, Puttemans PJ, Deprest J. The endoscopic localization of endometrial implants in the ovarian chocolate cyst. Fertil Steril 1994;61(6):1034–1038. DOI: 10.1016/s0015-0282(16)56752-1.
  6. Nezhat F, Nezhat C, Allan CJ, et al. Clinical and histologic classification of endometriomas. Implications for a mechanism of pathogenesis. J Reprod Med 1992;37(9):771–776. PMID: 1453396.
  7. Donnez J, Nisolle M, Gillet N, et al. Large ovarian endometriomas. Hum Reprod 1996;11(3):641–646. DOI: 10.1093/humrep/11.3.641.
  8. Marquardt RM, Kim TH, Shin JH, et al. Progesterone and estrogen signaling in the endometrium: What goes wrong in endometriosis. Int J Mol Sci 2019;20(15):3822. DOI: 10.3390/ijms20153822.
  9. Dutta S, Haggerty DK, Rappolee DA, et al. Phthalate exposure and long-term epigenomic consequences: A review. Front Genet 2020;11:405. DOI: 10.3389/fgene.2020.00405.
  10. Conforti A, Buonfantino C, Caprio F, et al. O-260: the role of environmental contaminants in the development of endometriosis: A systematic review. Abstracts of the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology. Hum Reprod 2018;31(suppl_1):i112–113. DOI: https://doi.org/10.1093/humrep/31.Supplement_1.1.
  11. Prasad B. Phthalate pollution: Environmental fate and cumulative human exposure index using the multivariate analysis approach. Environ Sci Process Impacts 2021;23(3):389–399. DOI: 10.1039/d0em00396d.
  12. Llarena N, Flyckt R. Strategies to preserve and optimize fertility for patients with endometriosis. J Endometr Pelvic Pain Disord 2017;9:98–104. DOI: 10.5301/jeppd.5000278.
  13. Garcia-Velasco JA, Arici A. Is the endometrium or oocyte/embryo affected in endometriosis? Hum Reprod 1999;14 Suppl 2:77–89. DOI: 10.1093/humrep/14.suppl_2.77.
  14. Holoch K, Lessey B. Endometriosis and infertility. Clin Obstet Gynecol 2010;53(2):429–438. DOI: 10.1097/GRF.0b013e3181db7d71.
  15. Oral E, Arici A, Olive DL, et al. Peritoneal fluid from women with moderate or severe endometriosis inhibits sperm motility: The role of seminal fluid components. Fertil Steril 1996;66(5):787–792. DOI: 10.1016/s0015-0282(16)58637-3.
  16. Macer ML, Taylor HS. Endometriosis and infertility. A review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am 2012;39(4):535–549. DOI: 10.1016/j.ogc.2012.10.002.
  17. Lyons RA, Djahanbakhch O, Saridogan E, et al. Peritoneal fluid, endometriosis, and ciliary beat frequency in the human fallopian tube. Lancet 2002;360:1221–1222. DOI: 10.1016/S0140-6736(02)11247-5.
  18. Ota H, Igarashi S, Kato N, et al. Aberrant expression of glutathione peroxidase in eutopic and ectopic endometrium in endometriosis and adenomyosis. Fertil Steril 2000;74(2):313–318. DOI: 10.1016/s0015-0282(00)00638-5.
  19. Ota H, Igarashi S, Sato N, et al. Involvement of catalase in the endometrium of patients with endometriosis and adenomyosis. Fertil Steril 2002;78(4):804–809. DOI: 10.1016/s0015-0282(02)03344-7.
  20. Morcos RN, Gibbons WE, Findley WE. Effect of peritoneal fluid on in vitro cleavage of 2-cell mouse embryos: possible role in infertility associated with endometriosis. Fertil Steril 1985;44(5):678–683. DOI: 10.1016/s0015-0282(16)48987-9.
  21. Yasui T, Hayashi K, Mizunuma H, et al. Association of endometriosis-related infertility with age at menopause. Maturitas 2011;69(3): 279–283. DOI: 10.1016/j.maturitas.2011.04.009.
  22. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789–1799. DOI: 10.1016/S0140-6736(04)17403-5.
  23. Santamaria X, Massasa EE, Taylor HS. Migration of cells from experimental endometriosis to the uterine endometrium. Endocrinology 2012;153:5566–5574. DOI: 10.1210/en.2012-1202.
  24. Kitajima M, Defrère S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril 2011;96(3):685–691. DOI: 10.1016/j.fertnstert.2011.06.064.
  25. Kitajima M, Dolmans MM, Donnez O, et al. Enhanced follicular recruitment and atresia in cortex derived from ovaries with endometriomas. Fertil Steril 2014;101(4):1031–1037. DOI: 10.1016/j.fertnstert.2013.12.049.
  26. Matsuzaki S, Schubert B. Oxidative stress status in normal ovarian cortex surrounding ovarian endometriosis. Fertil Steril 2010; 93(7):2431–2432. DOI: 10.1016/j.fertnstert.2009.08.068.
  27. Dolmans MM, Martinez-Madrid B, Gadisseux E, et al. Short-term transplantation of isolated human ovarian follicles and cortical tissue into nude mice. Reproduction 2007;134(2):253–262. DOI: 10.1530/REP-07-0131.
  28. David A, Van Langendonckt A, Gilliaux S, et al. Effect of cryopreservation and transplantation on the expression of kit ligand and anti-Mullerian hormone in human ovarian tissue. Hum Reprod 2012;27(4):1088–1095. DOI: 10.1093/humrep/des013.
  29. Westergaard CG, Byskov AG, Andersen CY. Morphometric characteristics of the primordial to primary follicle transition in the human ovary in relation to age. Hum Reprod 2007;22(8):2225–2231. DOI: 10.1093/humrep/dem135.
  30. Opøien HK, Fedorcsak P, Polec A, et al. Do endometriomas induce an inflammatory reaction in nearby follicles. Hum Reprod 2013;28(7):1837–1845. DOI: 10.1093/humrep/det087.
  31. Sanchez AM, Somigliana E, Vercellini P, et al. Endometriosis as a detrimental condition for granulosa cell steroidogenesis and development: From molecular alterations to clinical impact. J Steroid Biochem Mol Biol 2016;155(Pt A):35–46. DOI: 10.1016/j.jsbmb.2015.07.023.
  32. Toya M, Saito H, Ohta N, et al. Moderate and severe endometriosis is associated with alterations in the cell cycle of granulosa cells in patients undergoing in vitro fertilization and embryo transfer. Fertil Steril 2000;73(2):344–350. DOI: 10.1016/s0015-0282(99)00507-5.
  33. Nakahara K, Saito H, Saito T, et al. Ovarian fecundity in patients with endometriosis can be estimated by the incidence of apoptotic bodies. Fertil Steril 1998;69(5):931–935. DOI: 10.1016/s0015-0282(98) 00038-7.
  34. Sanchez AM, Viganò P, Quattrone F, et al. The WNT/β-catenin signaling pathway and expression of survival promoting genes in luteinized granulosa cells: endometriosis as a paradigm for a dysregulated apoptosis pathway. Fertil Steril 2014;101(6):1688–1696. DOI: 10.1016/j.fertnstert.2014.02.040.
  35. Sanchez AM, Viganò P, Somigliana E, et al. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: From pathophysiology to the potential endometrioma-mediated damage to the ovary. Hum Reprod Update 2014;20(2):217–230. DOI: 10.1093/humupd/dmt053.
  36. Mansour G, Sharma RK, Agarwal A, et al. Endometriosis-induced alterations in mouse metaphase II oocyte microtubules and chromosomal alignment: A possible cause of infertility. Fertil Steril 2010;94(5):1894–1899. DOI: 10.1016/j.fertnstert.2009.09.043.
  37. Sanchez AM, Papaleo E, Corti L, et al. Iron availability is increased in individual human ovarian follicles in close proximity to an endometrioma compared with distal ones. Hum Reprod 2014; 29(3):577–583. DOI: 10.1093/humrep/det466.
  38. Singh AK, Dutta M, Chattopadhyay R, et al. Intrafollicular interleukin-8, interleukin-12, and adrenomedullin are the promising prognostic markers of oocyte and embryo quality in women with endometriosis. J Assist Reprod Genet 2016;33(10):1363–1372. DOI: 10.1007/s10815-016-0782-5.
  39. Trombly DJ, Woodruff TK, Mayo KE. Roles for transforming growth factor beta superfamily proteins in early folliculogenesis. Semin Reprod Med 2009;27(1):14–23. DOI: 10.1055/s-0028-1108006.
  40. Goud PT, Goud AP, Joshi N, et al. Dynamics of nitric oxide, altered follicular microenvironment, and oocyte quality in women with endometriosis. Fertil Steril 2014;102(1):151–159.e5. DOI: 10.1016/j.fertnstert.2014.03.053.
  41. Sathananthan AH. Ultrastructure of the human egg. Hum Cell 1997;10:21–38. PMID: 9234062.
  42. Van Blerkom J. Intrafollicular influences on human oocyte developmental competence: Perifollicular vascularity, oocyte metabolism and mitochondrial function. Hum Reprod 2000;15 Suppl 2:173–188. DOI: 10.1093/humrep/15.suppl_2.173.
  43. May-Panloup P, Chrétien MF, Jacques C, et al. Low oocyte mitochondrial DNA content in ovarian insufficiency. Hum Reprod 2005;20(3):593–597. DOI: 10.1093/humrep/deh667.
  44. Xu B, Guo N, Zhang XM, et al. Oocyte quality is decreased in women with minimal or mild endometriosis. Sci Rep 2015;5:10779. DOI: 10.1038/srep10779.
  45. Pados G, Tsolakidis D, Assimakopoulos E, et al. Sonographic changes after laparoscopic cystectomy compared with three-stage management in patients with ovarian endometriomas: A prospective randomized study. Hum Reprod 2010;25(3):672–677. DOI: 10.1093/humrep/dep448.
  46. Arcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: To touch or not to touch. Hum Reprod 2009;24(3):496–501. DOI: 10.1093/humrep/den398.
  47. Busacca M, Riparini J, Somigliana E, et al. Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol 2006;195(2):421–425. DOI: 10.1016/j.ajog.2006.03.064.
  48. Muzii L, Bellati F, Bianchi A, et al. Laparoscopic stripping of endometriomas: A randomized trial on different surgical techniques. Part II: pathological results. Hum Reprod 2005;20(7):1987–1992. DOI: 10.1093/humrep/deh851.
  49. Muzii L, Bianchi A, Crocè C, et al. Laparoscopic excision of ovarian cysts: is the stripping technique a tissue-sparing procedure. Fertil Steril 2002;77(3):609–614. DOI: 10.1016/s0015-0282(01)03203-4.
  50. Muzii L, Bellati F, Palaia I, et al. Laparoscopic stripping of endometriomas: A randomized trial on different surgical techniques. Part I: clinical results. Hum Reprod 2005;20(7):1981–1986. DOI: 10.1093/humrep/dei007.
  51. Muzii L, Bianchi A, Bellati F, et al. Histologic analysis of endometriomas: What the surgeon needs to know. Fertil Steril 2007;87(2):362–366. DOI: 10.1016/j.fertnstert.2006.06.055.
  52. Muzii L, Marana R, Angioli R, et al. Histologic analysis of specimens from laparoscopic endometrioma excision performed by different surgeons: Does the surgeon matter? Fertil Steril 2011;95(6):2116–2119. DOI: 10.1016/j.fertnstert.2011.02.034.
  53. Hachisuga T, Kawarabayashi T. Histopathological analysis of laparoscopically treated ovarian endometriotic cysts with special reference to loss of follicles. Hum Reprod 2002;17(2):432–435. DOI: 10.1093/humrep/17.2.432.
  54. Matsuzaki S, Houlle C, Darcha C, et al. Analysis of risk factors for the removal of normal ovarian tissue during laparoscopic cystectomy for ovarian endometriosis. Hum Reprod 2009;24(6):1402–1406. DOI: 10.1093/humrep/dep043.
  55. Romualdi D, Franco Zannoni G, Lanzone A, et al. Follicular loss in endoscopic surgery for ovarian endometriosis: Quantitative and qualitative observations. Fertil Steril 2011;96(2):374–378. DOI: 10.1016/j.fertnstert.2011.05.078.
  56. Muzii L, Achilli C, Lecce F, et al. Second surgery for recurrent endometriomas is more harmful to healthy ovarian tissue and ovarian reserve than first surgery. Fertil Steril 2015;103(3):738–743. DOI: 10.1016/j.fertnstert.2014.12.101.
  57. Hadfield R, Mardon H, Barlow D, et al. Delay in the diagnosis of endometriosis: A survey of women from the USA and the UK. Hum Reprod 1996;11(4):878–880. DOI: 10.1093/oxfordjournals.humrep.a019270.
  58. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: A committee opinion. Fertil Steril 2014; (101):927–935. PMID: 24630080.
  59. Vercellini P, DE Matteis S, Somigliana E, et al. Long-term adjuvant therapy for the prevention of postoperative endometrioma recurrence: A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2013;92(1):8–16. DOI: 10.1111/j.1600-0412.2012.01470.x.
  60. Römer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet 2018;298(4):747–753. DOI: 10.1007/s00404-018-4864-8.
  61. Ebert AD, Dong L, Merz M, et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: The visanne study to assess safety in adolescents. J Pediatr Adolesc Gynecol 2017;30(5):560–567. DOI: 10.1016/j.jpag.2017.01.014.
  62. Gallagher JS, Missmer SA, Hornstein MD, et al. Long-term effects of gonadotropin-releasing hormone agonists and add-back in adolescent endometriosis. J Pediatr Adolesc Gynecol 2018;31(4): 376–381. DOI: 10.1016/j.jpag.2018.03.004.
  63. Irahara M, Uemura H, Yasui T, et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest 2001;52(4):217–222. DOI: 10.1159/000052978.
  64. Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2010;2010(12):CD008475. DOI: 10.1002/14651858.CD008475.pub2.
  65. Leyland N, Casper R, Laberge P, et al. Endometriosis: Diagnosis and Management. J Obstet Gynaecol Can 2010;32(7 Suppl 2):1–32. PMID: 21545757.
  66. Laufer MR. Helping “adult gynecologists” diagnose and treat adolescent endometriosis: Reflections on my 20 years of personal experience. J Pediatr Adolesc Gynecol 2011;24(5 Suppl):S13–S37. DOI: 10.1016/j.jpag.2011.07.005.
  67. Donnez J, Taylor RN, Taylor HS. Partial suppression of estradiol: A new strategy in endometriosis management. Fertil Steril 2017;107(3): 568–570. DOI: 10.1016/j.fertnstert.2017.01.013.
  68. Donnez J, Dolmans MM. Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review. J Clin Med 2021;10(5):1085. DOI: 10.3390/jcm10051085.
  69. Donnez J, Dolmans MM. GnRH Antagonists with or without Add-Back Therapy: A New Alternative in the Management of Endometriosis. Int J Mol Sci 2021;22(21):11342. DOI: 10.3390/ijms222111342.
  70. Surrey ES, Soliman AM, Agarwal SK, et al. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril 2019;112(2):298–304.e3. DOI: 10.1016/j.fertnstert.2019.02.031.
  71. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med 2017;377(1):28–40. DOI: 10.1056/NEJMoa1700089.
  72. Archer DF, Stewart EA, Jain RI, et al. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: Results from a phase 2a proof-of-concept study. Fertil Steril 2017;108(1): 152-160.e4. DOI: 10.1016/j.fertnstert.2017.05.006.
  73. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis. https://www.prnewswire.com/news-releases/abbott-and-neurocrine-announce-global-agreement-to-develop-and-commercialize-elagolix-for-the-treatment-of-endometriosis-96457079.html. Accessed: 2022-10-10.
  74. Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril 2012;98(6):1370–1379. DOI: 10.1016/j.fertnstert.2012.08.053.
  75. Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2014;10(5):261–275. DOI: 10.1038/nrendo.2013.255.
  76. Bilotas M, Meresman G, Stella I, et al. Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertil Steril 2010;93(8):2513–2518. DOI: 10.1016/j.fertnstert.2009.08.058.
  77. Almassinokiani F, Almasi A, Akbari P, et al. Effect of Letrozole on endometriosis-related pelvic pain. Med J Islam Repub Iran 2014;28:107. DOI: 10.1016/j.fertnstert.2010.05.021.
  78. Agarwal SK, Foster WG. Reduction in endometrioma size with three months of aromatase inhibition and progestin add-back. Biomed Res Int 2015;2015:878517. DOI: 10.1155/2015/878517.
  79. Cantor A, Tannus S, Son WY, et al. A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF. Reprod Biomed Online 2019;38(4):520–527. DOI: 10.1016/j.rbmo.2018.12.028.
  80. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: A prospective randomized trial. Hum Reprod 2004;19(1):160–167. DOI: 10.1093/humrep/deh035.
  81. Asante A, Taylor RN. Endometriosis: The role of neuroangiogenesis. Annu Rev Physiol 2011;73:163–182. DOI: 10.1146/annurev-physiol-012110-142158.
  82. Robert E, Musatti L, Piscitelli G, et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10(4):333–337. DOI: 10.1016/0890-6238(96)00063-9.
  83. Delgado-Rosas F, Gómez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 2011;142(5):745–755. DOI: 10.1530/REP-11-0223.
  84. Ricci E, Parazzini F, Motta T, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16(6):791–793. DOI: 10.1016/s0890-6238(02)00055-2.
  85. Colao A, Abs R, Bárcena DG, et al. Pregnancy outcomes following cabergoline treatment: Extended results from a 12-year observational study. Clin Endocrinol (Oxf) 2008;68:66–71. DOI: 10.1111/j.1365-2265.2007.03000.x
  86. DiVasta AD, Stamoulis C, Gallagher JS, et al. Nonhormonal therapy for endometriosis: A randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. F S Rep 2021;2(4):454–461. DOI: 10.1016/j.xfre.2021.07.003
  87. Kim YS, Kim YJ, Kim MJ, et al. Novel medicine for endometriosis and its therapeutic effect in a mouse model. biomedicines. 2020; 16;8(12):619. DOI: 10.3390/biomedicines8120619.
  88. Donnez J, Lousse JC, Jadoul P, et al. Laparoscopic management of endometriomas using a combined technique of excisional (cystectomy) and ablative surgery. Fertil Steril 2010;94(1):28–32. DOI: 10.1016/j.fertnstert.2009.02.065.
  89. Tsolakidis D, Pados G, Vavilis D et al. The impact on ovarian reserve after laparoscopic ovarian cystectomy versus three-stage management in patients with endometriomas: a prospective randomized study. Fertil. Steril. 2010;94(1):71–77. DOI: 10.1016/j.fertnstert.2009.01.138.
  90. Saito N, Yamashita Y, Okuda K, et al. Comparison of the impact of laparoscopic endometriotic cystectomy and vaporization on postoperative serum anti-Mullerian hormone levels. Asian J Endosc Surg 2018;11(1):23–29. DOI: 10.1111/ases.12412.
  91. Candiani M, Ottolina J, Posadzka E, et al. Assessment of ovarian reserve after cystectomy versus ‘one-step’ laser vaporization in the treatment of ovarian endometrioma: A small randomized clinical trial. Hum Reprod 2018;33(12):2205–2211. DOI: https://doi.org/10.1093/humrep/dey305.
  92. Crestani A, Merlot B, Dennis T, et al. Laparoscopic sclerotherapy for an endometrioma in 10 steps. Fertil Steril 2022;117(5):1102–1103. DOI: 10.1016/j.fertnstert.2022.01.036.
  93. De Cicco Nardone A, Carfagna P, De Cicco Nardone C, et al. Laparoscopic ethanol sclerotherapy for ovarian endometriomas: preliminary results. J Minim Invasive Gynecol 2020;27(6):1331–1336. DOI: 10.1016/j.jmig.2019.09.792.
  94. Saeki A, Matsumoto T, Ikuma K et al. The vasopressin injection technique for laparoscopic excision of ovarian endometrioma: a technique to reduce the use of coagulation. J. Minim. Invasive Gynecol. 2010;17(2):176–179. DOI: 10.1016/j.jmig.2009.11.004.
  95. Chung JPW, Law TSM, Mak JSM, et al. Ovarian reserve and recurrence 1 year post-operatively after using haemostatic sealant and bipolar diathermy for haemostasis during laparoscopic ovarian cystectomy. Reprod Biomed Online 2021;43(2):310–318. DOI: 10.1016/j.rbmo.2021.05.003.
  96. Shaltout MF, Elsheikhah A, Maged AM, et al. A randomized controlled trial of a new technique for laparoscopic management of ovarian endometriosis preventing recurrence and keeping ovarian reserve. J Ovarian Res 2019;12(1):66. DOI: 10.1186/s13048-019-0542-0.
  97. Baracat CMF, Abdalla-Ribeiro HSA, Araujo RSDC, et al. The impact on ovarian reserve of different hemostasis methods in laparoscopic cystectomy: a systematic review and meta-analysis. Rev Bras Ginecol Obstet 2019;41(6):400–408. DOI: 10.1055/s-0039-1692697.
  98. Ding W, Li M, Teng Y. The impact on ovarian reserve of haemostasis by bipolar coagulation versus suture following surgical stripping of ovarian endometrioma: a meta-analysis. Reprod Biomed Online 2015;30(6):635–642. DOI: 10.1016/j.rbmo.2015.02.012.
  99. Albanese G, Kondo KL. Pharmacology of sclerotherapy. Semin Intervent Radiol 2010;27(4):391–399. DOI: 10.1055/s-0030-1267848.
  100. Yazbeck C, Madelenat P, Ayel JP, et al. Ethanol sclerotherapy: A treatment option for ovarian endometriomas before ovarian stimulation. Reprod Biomed Online 2009;19(1):121–125. DOI: 10.1016/s1472-6483(10)60055-7.
  101. Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: Systematic review and meta-analysis Fertil and Steril 2017;108(1):117–124.e5. DOI: 10.1016/j.fertnstert.2017. 05.015.
  102. Noma J, Yoshida N. Efficacy of ethanol sclerotherapy for ovarian endometriomas. Int J Gynaecol Obstet 2001;72(1):35–39. DOI: 10.1016/s0020-7292(00)00307-6.
  103. Kim GH, Kim PH, Shin JH, et al. Ultrasound-guided sclerotherapy for the treatment of ovarian endometrioma: An updated systematic review and meta-analysis. Eur Radiol 2022;32(3):1726–1737. DOI: 10.1007/s00330-021-08270-5.
  104. Martinez-Garcia JM, Candas B, Suarez-Salvador E, et al. Comparing the effects of alcohol sclerotherapy with those of surgery on anti-Müllerian hormone and ovarian reserve after endometrioma treatment. A prospective multicenter pilot cohort study. Eur J Obstet Gynecol Reprod Biol 2021;259:60–66. DOI: 10.1016/j.ejogrb.2021.01.027.
  105. Begum MR, Ehsan M, Ehsan N, et al. Sclerotherapy with ethanol: An effective and safe alternative to potentially complex surgical treatment of recurrent ovarian endometrioma. JSAFOG 2015;7(2): 97–101. DOI: 10.5005/jp-journals-10006-1335.
  106. Shawk H E, Elmorsi M, Samir A, et al. In situ methotrexate injection after transvaginal ultrasound-guided aspiration of ovarian endometriomas: A randomized controlled trial. Middle East Fertility Society Journal. 2011;16(3):224–231. DOI: https://doi.org/10.1016/j.mefs.2011.02.002.
  107. Shawki HE. The impact of in situ methotrexate injection after transvaginal ultrasound-guided aspiration of ovarian endometriomas on ovarian response and reproductive outcomes during IVF-cycles. Middle East Fertil Soc 2012;17:82–88. DOI: 10.1016/j.mefs.2011.07.002.
  108. Fisch JD, Sher G. Sclerotherapy with 5% tetracycline is a simple alternative to potentially complex surgical treatment of ovarian endometriomas before in vitro fertilization. Fertil Steril 2004;82(2):437–441. DOI: 10.1016/j.fertnstert.2004.01.031.
  109. Cohen J, Ziyyat A, Naoura I, et al. effect of induced peritoneal endometriosis on oocyte and embryo quality in a mouse model. J Assist Reprod Genet 2015;32(2):263–270. DOI: 10.1007/s10815-014-0390-1.
  110. Agostinis C, Balduit A, Mangogna A, et al. Immunological basis of the endometriosis: the complement system as a potential therapeutic target. Front Immunol 2021;11:599117. DOI: 10.3389/fimmu.2020.599117.
  111. Lee YH, Yang JX, Allen JC, et al. Elevated peritoneal fluid ceramides in human endometriosis-associated infertility and their effects on mouse oocyte maturation. Fertil Steril 2018;110(4):767–777.e5. DOI: 10.1016/j.fertnstert.2018.05.003.
  112. Vercellini P, Somigliana E, Vigano P, et al. Surgery for endometriosis-associated infertility: A pragmatic approach. Hum Reprod 2009;24(2):254–269. DOI: 10.1093/humrep/den379.
  113. Muzii L, DI Tucci C, Galati G, et al. Endometriosis-associated infertility: Surgery or IVF? Minerva Obstet Gynecol 2021;73(2):226–232. DOI: 10.23736/S2724-606X.20.04765-6.
  114. Duckelmann AM, Taube E, Abesadze E, et al. When and how should peritoneal endometriosis be operated on in order to improve fertility rates and symptoms? The experience and outcomes of nearly 100 cases. Arch Gynecol Obstet 2021;304(1):143–155. DOI: 10.1007/s00404-021-05971-6.
  115. Adamson GD, Pasta DJ. Endometriosis fertility index: The new, validated endometriosis staging system. Fertil Steril 2010;94(5): 1609–1615. DOI: 10.1016/j.fertnstert.2009.09.035.
  116. Pirtea P, Vulliemoz N, Ziegler D de, et al. Infertility workup: Identifying endometriosis. Fertil Steril 2022;118(1):29–33. DOI: 10.1016/j.fertnstert.2022.03.015.
  117. Noble LS, Takayama K, Zeitoun KM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82(2):600–606. DOI: 10.1210/jcem.82.2.3783.
  118. Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev 2019;40(4):1048–1079. DOI: 10.1210/er.2018-00242.
  119. Barragan F, Irwin JC, Balayan S, et al. Human endometrial fibroblasts derived from mesenchymal progenitors inherit progesterone resistance and acquire an inflammatory phenotype in the endometrial niche in endometriosis. Biol Reprod 2016;94(5):118. DOI: 10.1095/biolreprod.115.136010.
  120. Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod 2007;77(4):681–687. DOI: 10.1095/biolreprod.107.061804.
  121. Aghajanova L, Tatsumi K, Horcajadas JA, et al. Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod 2011;84(4):801–815. DOI: 10.1095/biolreprod.110.086181.
  122. Lessey BA, Lebovic DI, Taylor RN. Eutopic endometrium in women with endometriosis: Ground zero for the study of implantation defects. Semin Reprod Med 2013;31(2):109–124. DOI: 10.1055/s-0032-1333476.
  123. Brosens I, Brosens JJ, Benagiano G. The eutopic endometrium in endometriosis: Are the changes of clinical significance? Reprod Biomed Online 2012;24:496–502. DOI: 10.1016/j.rbmo.2012.01.022.
  124. Maia H Jr, Casoy J, Correia T, et al. The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis. Gynecol Endocrinol 2008;24:123–128. DOI: 10.1080/09513590801890816.
  125. Bishop LA, Gunn J, Jahandideh S, et al. Endometriosis does not impact live-birth rates in frozen embryo transfers of euploid blastocysts. Fertil Steril 2021;115:416–422. DOI: 10.1016/j.fertnstert.2020.07.050.
  126. Tokushige N, Markham R, Russell P, et al. Effects of hormonal treatment on nerve fibers in endometrium and myometrium in women with endometriosis. Fertil Steril 2008;90:1589–1598. DOI: 10.1016/j.fertnstert.2007.08.074.
  127. Patel BG, Rudnicki M, Yu J, et al. Progesterone resistance in endometriosis: Origins, consequences and interventions. Acta Obstet Gynecol Scand 2017;96:623–632. DOI: 10.1111/aogs.13156.
  128. Bishop LA, Gunn J, Jahandideh S, Devine K, Decherney AH, Hill MJ. Endometriosis does not impact live-birth rates in frozen embryo transfers of euploid blastocysts. Fertil Steril 2021;115:416–422.
  129. Hwu YM, Wu FS, Li SH, et al. The impact of endometrioma and laparoscopic cystectomy on serum anti-mullerian hormone levels. Reprod Biol Endocrinol 2011;9:80. DOI: 10.1186/1477-7827-9-80.
  130. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update 2009;15:441–61.
  131. De Vos M, Smitz J, Woodruff TK. Fertility preservation in women with cancer. Lancet 2014;384:1302–1310. PMID: 25283571.
  132. Elizur SE, Chian RC, Holzer HE, et al. Cryopreservation of oocytes in a young woman with severe and symptomatic endometriosis: A new indication for fertility preservation. Fertil Steril 91(1), 293.e1–293.e2933. DOI: 10.1016/j.fertnstert.2007.06.040.
  133. Raad J, Sonigo C, Tran C, et al. Oocyte vitrification for preserving fertility in patients with endometriosis: First observational cohort study. Eur J Obstet Gynecol Reprod Biol 2018;220:140–141. PMID: 29221758.
  134. Doyle JO, Richter KS, Lim J, et al. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril 2016;105:459–466. DOI: 10.1016/j.fertnstert.2015.10.026.
  135. Leung AQ, Baker K, Vaughan D, et al. Clinical outcomes and utilization from over a decade of planned oocyte cryopreservation. Reprod BioMed Online 2021;43(4):671–679. DOI: 10.1016/j.rbmo.2021.06.024.
  136. Streuli I, Benard J, Hugon-Rodin J, et al. Shedding light on the fertility preservation debate in women with endometriosis: a SWOT analysis. Eur J Obstet Gynecol Reprod Biol 2018;229:172–178. DOI: 10.1016/j.ejogrb.2018.08.577.
  137. Diaz-Garcia C, Domingo J, Garcia-Velasco JA, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: A prospective cohort study. Fertil Steril 2018;109:478–485. DOI: 10.1016/j.fertnstert.2017.11.018.
  138. Forman EJ. Ovarian tissue cryopreservation: Still experimental? Fertil Steril 2018;109:443–444. DOI: 10.1016/j.fertnstert.2017.12.031.
  139. Donnez J, Squifflet J, Dolmans MM, et al. Orthotopic transplantation of fresh ovarian cortex: A report of two cases. Fertil Steril 2005;84:1018.e1–1018.e3. DOI: 10.1016/j.fertnstert.2005.06.011.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.